Decitabine 化学構造
分子量: 228.21

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare DNA Methyltransferase Inhibitors
    DNA Methyltransferase製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 デシタビンは、HL-60とKG1a細胞の438nMと4.38nMのIC50によるDNAメチル化の強力な阻害剤です。
ターゲット DNA methyltransferase (HL-60) DNA methyltransferase (KG1a)
IC50 100 ng/mL 1 ng/mL [1]
In vitro試験 Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
Eca109 MoS2SpVv[3Srb36gRZN{[Xl? MmrwNE42yqEQvF2= MlX0NlQhcA>? NIm2R|Z4[XSnch?= MX\tc4R2dGG2ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCPQVfFMWEhdWWvYnXydy=> M4ThdlI2OTJ|MEiy
Eca109 NGrhSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPVfJExNjVxMj61M|Uh|ryP M2jaeVI1NzR6L{eyJIg> M4\ONpdifGW{ NWq4WoFjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MY[yOVEzOzB6Mh?=
Eca109 M1q2bWZ2dmO2aX;uJGF{e2G7 NXuwXJNWOC53wrFOwG0> MVS2M|EzNzJ2IHi= Mk\Ce4F1\XJ? Mo\YbY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= M1nrb|I2OTJ|MEiy
Eca109 NWryXJllTnWwY4Tpc44hSXO|YYm= MnO2NE42yqEQvF2= M4nBfVI1KGh? NVnL[Xhof2G2ZYK= MkTpbY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? MX2yOVEzOzB6Mh?=
Eca109 M2q2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPPNE42yqEQvF2= MmnZNlQhcA>? M{\iVZdifGW{ M1ToSolv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> MYiyOVEzOzB6Mh?=
Eca109 MXLGeY5kfGmxbjDBd5NigQ>? NXXZeHNLOC53L{Gg{txO NFjTfIQzPCCq MmDhe4F1\XJ? Mnnp[IVkemWjc3XzJIV5eHKnc4Ppc44hd2ZiTl[t{tpDOiCjbnSgUW1ROg>? NVPZOGFrOjVzMkOwPFI>
SW1116  MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKwMlUwOS9{L{Wg{txO NH3vU441QCCq MnfZSG1UVw>? MX7lcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u MorvNlQ5PzR{OE[=
LOVO NFyyRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHINE42NzFxMj:1JO69VQ>? NXfwOFM1PDhiaB?= Mn\LSG1UVw>? NILmbmZmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v M3vYe|I1QDd2Mki2
SW1116  M1i2SGZ2dmO2aX;uJGF{e2G7 NH20TmUyOCEQvF2= MYO0PEBp NFLUTWhFVVOR NUP3Z4hwcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk M3vkRVI1QDd2Mki2
LOVO Ml3vSpVv[3Srb36gRZN{[Xl? NILBNHYyOCEQvF2= NFvXeHo1QCCq Mm\mSG1UVw>? MYDpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> NYL5XZo6OjR6N{SyPFY>
SW1116  NGrXe|hCeG:ydH;zbZMhSXO|YYm= NUnKSIw{OTBizszN M1riO|Q5KGh? NInpUJZFVVOR M17HUoVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> NWe2eGRxOjR6N{SyPFY>
LOVO M1nRUWFxd3C2b4Ppd{BCe3OjeR?= NWfQR|ZbOTBizszN MUO0PEBp M1z4d2ROW09? MVTlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NF;J[3MzPDh5NEK4Oi=>
RPMI-8226 M2Hub2Fxd3C2b4Ppd{BCe3OjeR?= MlTnNU8zKM7:TR?= M362WVQ5Nzd{L{m2JIg> M1TOd2ROW09? MXrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NEDtbXczPDh|M{GwPC=>
OPM-2  NVn4RVZzSXCxcITvd4l{KEG|c3H5 NXe4e41lOS9{IN88US=> Mn\tO|IwQTZxMUKwJIg> MnrJSG1UVw>? MX3pcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mn\BNlQ5OzNzMEi=
JJN3  NYXWWpFlSXCxcITvd4l{KEG|c3H5 MoK3NE42NzFizszN M{KydFI1NzR6IHi= NGLKNpRFVVOR NHzXSYdqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MWqyOFg{OzFyOB?=
NCI-H929  MlPjRZBweHSxc3nzJGF{e2G7 M3TPS|EwOiEQvF2= M4LQfFczNzl4L{GyNEBp NXrFdZJDTE2VTx?= NVfkS2kxcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NIH3TYwzPDh|M{GwPC=>
RPMI-8226 NFHjNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXixM|Ih|ryP NYrIWGM{OjRxNEivO|IhcA>? NXj0emp7TE2VTx?= M{fWb4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MYKyOFg{OzFyOB?=
OPM-2  NVzqZYM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn2dZMyNzJizszN MX[yOE81QC95MjDo NHTaT3FFVVOR MoTwZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MY[yOFg{OzFyOB?=
JJN3  MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\YbFAvPS9zIN88US=> NEjiVlkzPC92OD:3NkBp NVjBUpR{TE2VTx?= M3n4fYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 M3vMeVI1QDN|MUC4
NCI-H929  Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4GwcFEwOiEQvF2= NXruOWt6OjRxNEivO|IhcA>? Mni3SG1UVw>? NUez[HNk[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MmizNlQ5OzNzMEi=
HeLa NWDa[VlCU2mwYYPlJGF{e2G7 Mn\QT4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> MXOyOFc5ODB7OB?=
HeLa MYPLbY5ie2ViQYPzZZk> NGnJTIlMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> M1PKZVI1PzhyMEm4
HeLa M4TwTGtqdmG|ZTDBd5NigQ>? NW\5c5pZU2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? Mo\xNlQ4QDByOUi=
HeLa MXTLbY5ie2ViQYPzZZk> M3rCO2tqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> M{L5UFI1PzhyMEm4
NB4 NEW2dplHfW6ldHnvckBCe3OjeR?= MnT5Nk42NzVxNz61M|ExKM7:TR?= MUCyOEBp MWDEUXNQ MWnpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh MUCyOFQ5PDh5MB?=
CD4+ CD25− T  NVLMWXRwTnWwY4Tpc44hSXO|YYm= MXmxM|Uh|ryP Ml;tdoVlfWOnUzDncI9j[WxiRF7BJI1mfGi7bHH0bY9v NV3KVFBzOjR2N{[zOlA>
BV-173 NGrEeVhCeG:ydH;zbZMhSXO|YYm= MXGwMlI2NzBwNT:wMlc2NzFizszN M{jnTlQ5Nzd{L{m2JIg> MXJCpHBDWw>? M4G5Zolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MmPCNlQ1OjN4MUO=
ML-1 NXjxUmMySXCxcITvd4l{KEG|c3H5 MUWwMlI2NzBwNT:wMlc2NzFizszN MWG0PE84Oi97NjDo MlfWxsBRSlN? MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M3HUelI1PDJ|NkGz
HL-60 MkDtRZBweHSxc3nzJGF{e2G7 MUSwMlI2NzBwNT:wMlc2NzFizszN M3zqW|Q5Nzd{L{m2JIg> MmjqxsBRSlN? MoLlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M3;nZVI1PDJ|NkGz
KG-1a NGS0XVZCeG:ydH;zbZMhSXO|YYm= NV;SeGw5OC5{NT:wMlUwOC55NT:xJO69VQ>? NXvnW3FrPDhxN{KvPVYhcA>? NF\XZZrDqFCEUx?= MmTtbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NHrjNHYzPDR{M{[xNy=>
BV-173 M1XFS2Z2dmO2aX;uJGF{e2G7 NGHMT5MzPTBxNUCwcm0> Mm\UOFghcA>? MWtCpHBDWw>? M3racIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NEO3WWczPDR{M{[xNy=>
CEM MlHkSpVv[3Srb36gRZN{[Xl? MlXvNlUxNzVyMH7N NWfkbHFVPDhiaB?= MV5CpHBDWw>? NX;qdop5cW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl M3G3bFI1PDJ|NkGz
HL-60 M1T1SmZ2dmO2aX;uJGF{e2G7 NWruTVNpOjVyL{WwNI5O NWTh[HZUPDhiaB?= M1rZXuKhWEKV NYTMR4VLcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NEDJPHIzPDR{M{[xNy=>
ML-1 NYrDc|Q1TnWwY4Tpc44hSXO|YYm= MYCyOVAwPTBybl2= MmHKOFghcA>? NEnsZXrDqFCEUx?= M3fHcIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NH;WSnIzPDR{M{[xNy=>
DLD-1 MVLGeY5kfGmxbjDBd5NigQ>? NGD4emIzPTBxNUCwcm0> NEfDfHg1QCCq NFTPVIbDqFCEUx?= MlrM[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? M2XFVFI1PDJ|NkGz
HCT-116 NYfGVHZNTnWwY4Tpc44hSXO|YYm= M4\PPVI2OC93MEDuUS=> NEHLOG41QCCq NGnBS2PDqFCEUx?= M37kWIRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M3LSeFI1PDJ|NkGz
U937-A/E-9/14/18  MYnBdI9xfG:|aYOgRZN{[Xl? M3vZN|AvODFxMD6xM|EwOTBizszN MUi0PEBp NV3ie4JEcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NImwWG8zPDNyMES1Oi=>
HT29 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7sc2l6PzJiaB?= NGSwVYdKSzVyPUG0NFDDuTF5OTFOwG0> MUSyOFE4OjB4MR?=
SW48 NEf6dIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKzTHZpPzJiaB?= MX\JR|UxRTF3LkNCtVYvOiEQvF2= MnrINlQyPzJyNkG=
HCT116 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYm3NkBp MkD3TWM2OD1zLkhCtVAvPCEQvF2= NWHI[WZoOjRzN{KwOlE>
HepG2 M3zjTWZ2dmO2aX;uJGF{e2G7 MUKwMlUwOSEQvF2= NHjuPY0zPCCq M1XKV2ROW09? NH[4W2t2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= Mn[4NlQyPDZ6N{S=
LS174T MXfGeY5kfGmxbjDBd5NigQ>? MXuwMlUwOSEQvF2= NXfibYh6OjRiaB?= MlfCSG1UVw>? MnLRcIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= NIG5enAzPDF2Nki3OC=>
HepG2 NG\mcGNCeG:ydH;zbZMhSXO|YYm= MYqxM|ExNzFyMDFOwG0> M{jPOFch\A>? M37qRmROW09? NHXxcG5qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVOyOFE1Pjh5NB?=
LS174T NV\YTZVFSXCxcITvd4l{KEG|c3H5 MnrSNU8yOC9zMECg{txO MX63JIQ> MnjsSG1UVw>? NVf6e3ZvcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M362PFI1OTR4OEe0
QBC-939 NUDwfFBvSXCxcITvd4l{KEG|c3H5 M{nHclEwOTBxMUCwJO69VQ>? MXG3JIQ> NVrKfmVKTE2VTx?= NYfOZmx4cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2nmdVI1OTR4OEe0
U251 NHu1[lVCeG:ydH;zbZMhSXO|YYm= NUG4empFOS9zMD:xNFAh|ryP MVG3JIQ> NVjYWVBoTE2VTx?= NXfETWs2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3rreVI1OTR4OEe0
HL-60 Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mly3NUDPxE1? NEXnUGw1QCCq NH\LboJqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= MVeyOFAxODN{NB?=
MDA‑MB‑453 M2HiSGZ2dmO2aX;uJGF{e2G7 NHLKeVAxNjJxMTFOwG0> NVjsUlB3PzJiaB?= MWPjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= NYDBU2I2OjN6NESyNlg>
HCC1569 NYfyTVFQTnWwY4Tpc44hSXO|YYm= NIDwO4oxNjJxMTFOwG0> M4PReVczKGh? MUXjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= MW[yN|g1PDJ{OB?=
BT‑474 Mnj5SpVv[3Srb36gRZN{[Xl? MYewMlIwOSEQvF2= NF;ydIU4OiCq MoDYZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg Mo\5NlM5PDR{Mki=
AGS NEn5WIdCeG:ydH;zbZMhSXO|YYm= MkXPOU8yOC9{MD:1NEDPxE1? NFrsSXE1QMLiaNMg MVXEUXNQ NGPxPXFqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? M4nDbVI{PTh{N{i0
A549 NXX0cYhVSXCxcITvd4l{KEG|c3H5 MUe1M|ExNzJyL{WwJO69VQ>? NYrlOWtNPDkEoHlCpC=> NV7qTXM6TE2VTx?= NHzJUGlqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? MnzmNlM2QDJ5OES=
AGS  Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTrOU8yOC9{MD:1NEDPxE1? MnXTOFjDqGkEoB?= NEfVOGNFVVOR NWHScIJncW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh NIS3eVkzOzV6Mke4OC=>
Kasumi-1 M2DtSmFxd3C2b4Ppd{BCe3OjeR?= NFj4VoYxNjVizszN NV3ze|RqPDkEoHlCpC=> NU\rS4w{\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> M3iwdVI{PDl|M{S4
OCI-AML3 NUC5[mhQSXCxcITvd4l{KEG|c3H5 NH;WXXMzNjVizszN MV20POKhcMLi NFLvb29l\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NEfOcFEzOzR7M{O0PC=>
MV4-11 NUDYTlI4SXCxcITvd4l{KEG|c3H5 M{j2TVIvPSEQvF2= NXX1XVFNPDkEoHlCpC=> M2HCe4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MWqyN|Q6OzN2OB?=
NK  NEj1TXhEgXSxdH;4bZR6KEG|c3H5 NHHuXFYxNjB{LUKwJO69VQ>? NV\LbnVtPSCm NFXsOohl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n NHfwfmwzOzN{OEC4PC=>
NK  MUXBdI9xfG:|aYOgRZN{[Xl? M2\sWlAvODJvMkCg{txO NELWS5g2KGR? NEPpUJdl\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? NGL3bowzOzN{OEC4PC=>
NK  NFP5XXpHfW6ldHnvckBCe3OjeR?= NV\s[JpDOC5yMT2yNEDPxE1? NHjwc5U2KGR? MXvjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl NHrGVGEzOzN{OEC4PC=>
MOLT4/DNR MlPpSpVv[3Srb36gRZN{[Xl? M17pTFUh|ryP NX:4Zoh5PCCm M1jmXpJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v M3;3blI{ODZyNUew
Jurkat/DOX MU\GeY5kfGmxbjDBd5NigQ>? NGGwS2Y2KM7:TR?= MYK0JIQ> MlTjdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> NHTSXlEzOzB4MEW3NC=>
MOLT4/DNR Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW1OUDPxE1? NUP6WpY{PCCm NUfRcGRnemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> M4fzXVI{ODZyNUew
Jurkat/DOX M17yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rZclUh|ryP MYG0JIQ> M4DFbpJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= NH7EdlkzOzB4MEW3NC=>
ccRCC  M3LyRWFxd3C2b4Ppd{BCe3OjeR?= MmfwNE4xOS1zMN88US=> M1zN[FczKGh? NX;pb4JOTE2VTx?= NXLr[ppXcGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= NHexbXQzOjh{NkS2Oy=>
TNBC  NXHiW4g{SXCxcITvd4l{KEG|c3H5 MVKwMlAyNTFyzszN M4fxSVczKGh? MlHrSG1UVw>? M{PWcohieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? NFv0b4gzOjh{NkS2Oy=>
A498 NVvSW|hvSXCxcITvd4l{KEG|c3H5 MV:wMlAyNTFyzszN NVHQOVFQPzJiaB?= Mmj3SG1UVw>? NX3uflUxcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? M3HuWFIzQDJ4NE[3
KIJ265T M4jycGFxd3C2b4Ppd{BCe3OjeR?= NXLMeZRYOC5yMT2xNO69VQ>? NEHaOGw4OiCq Mn:zSG1UVw>? NED2VHlqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NFjtW44zOjh{NkS2Oy=>
MDA-231 NI[2epRCeG:ydH;zbZMhSXO|YYm= MUCwMlAyNTFyzszN Mn3EO|IhcA>? NF31OnpFVVOR NXfQN5EzcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? M1PsVFIzQDJ4NE[3
BT-20 M4TH[2Fxd3C2b4Ppd{BCe3OjeR?= MlrCNE4xOS1zMN88US=> MYi3NkBp NGPYbo1FVVOR M37yW4lv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NGXFWG8zOjh{NkS2Oy=>
U937 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[1MVIxKM7:TR?= Mlu1NlQwPDhxN{KgbC=> M1HMNolv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MnriNlI4PjdyMkG=
HL60 NYLj[XFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXsXYY2NTJyIN88US=> NUXI[4tqOjRxNEivO|IhcA>? M1L4bIlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NVjtbZk4OjJ5NkewNlE>
U937 M1W1e2Fxd3C2b4Ppd{BCe3OjeR?= Ml;5NVUh|ryP NUjmOo1oOjRxNEivO|IhcA>? MVnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NE\TUnUzOjd4N{CyNS=>
HL60 NXXVeVRISXCxcITvd4l{KEG|c3H5 NVLZVplKOTVizszN MkLGNlQwPDhxN{KgbC=> M4\PR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGfnNGozOjd4N{CyNS=>
LS411N  NF[ycHFCeG:ydH;zbZMhSXO|YYm= M3;rOVAvPSEQvF2= M{OxWVczKGh? Ml3PbY5kemWjc3XzJGZieyCvUl7BJIxmfmWu M{\GVFIzPDZzNkm1
MDA-MB-231 NH\QUodCeG:ydH;zbZMhSXO|YYm= MUKxNEDPxE1? Mmn4OFghcA>? NEHsUplz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NITrO4wzOTh6N{[5Oy=>
MCF-7  NHTVUXVCeG:ydH;zbZMhSXO|YYm= NIjBN4EyOCEQvF2= NUHpfGNUPDhiaB?= NVX1RoY4emWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{LIWVIyQDh5Nkm3
A375 M2DmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq4NE42KM7:TR?= MnTFNU82NzhiZB?= NIXXTWRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NIPTZVEzOTd7Nk[yNi=>
SKMEL1 M1ix[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXM[HU{OC53IN88US=> MUCxM|UwQCCm MU\pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M1flVlIyPzl4NkKy
SKMEL3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\QflQxNjVizszN NX\leVUxOS93L{ig[C=> NF\BZ45qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M3LETlIyPzl4NkKy
SKMEL28 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPWNE42KM7:TR?= M4i2XlEwPS96IHS= MXnpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M{\JXVIyPzl4NkKy
MeWo NVTpOWtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nLelAvPSEQvF2= MnPsNU82NzhiZB?= M13afIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NFjKZmszOTd7Nk[yNi=>
B16 NYC3VXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfnOYR4OC53IN88US=> M4S4cVEwPS96IHS= MmLEbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M1myelIyPzl4NkKy
Ly 1 NF\vcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPsNlQhcA>? NHnQdJBKSzVyPUeuN{DPxE1? NYT0cnNmOjF5N{KwOFk>
Ly 7 Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrCcnA{OjRiaB?= M3XBW2lEPTB;MUCuO{DPxE1? MWOyNVc4OjB2OR?=
Su-DHL6 NVTjXYtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LhNlI1KGh? NF3tXYxKSzVy78{eNlAh|ryP MXqyNVc4OjB2OR?=
Ly 10 M{jx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUeyOEBp M2T1VWlEPTExvK6yNEDPxE1? MnLPNlE4PzJyNEm=
RIVA M1\MPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWyOEBp NEKxN3RKSzVy78{eNlAh|ryP M3q2N|IyPzd{MES5
Su-DHL2 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzDXHgzPCCq M{XHR2lEPTExvK6yNEDPxE1? NEG4UngzOTd5MkC0PS=>
Ly 1 NW\N[W9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq0PEBp NW\sRpl6UUN3ME2wMlM1KM7:TR?= NXfJT3p3OjF5N{KwOFk>
Ly 7 M1fYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUm0PEBp NI[wWFVKSzVyPUCuNFI2KM7:TR?= NITLZlUzOTd5MkC0PS=>
Su-DHL6 NI\LN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nwVVQ5KGh? NH60S4tKSzVy78{eNlAh|ryP MoTLNlE4PzJyNEm=
Ly 10 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInHN5o1QCCq M4HBWmlEPTB;MT64JO69VQ>? MmPiNlE4PzJyNEm=
RIVA MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW4cmxoPDhiaB?= M2[5cmlEPTExvK6yNEDPxE1? Mm[1NlE4PzJyNEm=
Su-DHL2 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[0PEBp M1\YZ2lEPTB;MUeuOEDPxE1? NXz0OGlHOjF5N{KwOFk>
Ly 1 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H2clczKGh? M4\CO2lEPTB;MD6wNUDPxE1? M1XONVIyPzd{MES5
Ly 7 NXnFWFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[0blczKGh? NETlPWJKSzVyPUCuNFE5KM7:TR?= M3XSV|IyPzd{MES5
Su-DHL6 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLiN4lYPzJiaB?= NGrvNJBKSzVyPUGuOkDPxE1? Mn;WNlE4PzJyNEm=
Ly 10 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUG3NkBp MXfJR|UxRTFwMjFOwG0> M{TWTFIyPzd{MES5
RIVA NGPyfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXkTHY4OiCq NXXqe2ZtUUN3MP-8olIxKM7:TR?= M3PJflIyPzd{MES5
Su-DHL2 M2[wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLkeWtDPzJiaB?= NG\QbppKSzVyPUGxMlIh|ryP Ml\GNlE4PzJyNEm=

... Click to View More Cell Line Experimental Data

In vivo試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]
臨床試験 Decitabine is currently in Phase I clinical trials in patients with Higher-risk MDS and MDS/AML Receiving Allogeneic Stem Cell Transplantation.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

DNA synthesis assay The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.

細胞アッセイ: [1]

細胞株 HL-60 and KG1a
濃度 0-500 nM
反応時間 96 hours
実験の流れ For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.

動物実験: [2]

動物モデル KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
製剤 Decitabine is dissolved in sterile PBS .
投薬量 ≤2.5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Decitabine SDF
分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管 3年-20℃
2年-80℃in solvent
別名 Deoxycytidine
溶解度 (25°C) * In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one

文献中の引用 (6)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related DNAメチルトランスフェラーゼ 阻害剤

最近チェックしたアイテム

Tags: Decitabineを買う | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ